---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-22-000114"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2022-05-31T23:59:59+00:00"
generated_at: "2026-06-25T05:57:09.678569+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Cam Gallagher as President, effective May 30, 2022

## Summary
- Cam Gallagher, formerly Executive Director and Board member, appointed President, replacing Kimberly Blackwell.
- Initial annual base salary: $560,000; eligible for 50% target bonus.
- Received stock options for 333,218 shares and RSUs for 111,072 shares, vesting over 4 years.
- Gallagher has ties to Recurium IP, which received $10M milestone fees from Zentalis in 2021.
- Employment is at-will; severance includes 12 months salary plus prorated bonus on qualifying termination.

## SEC filing metadata
- accession: 0001725160-22-000114
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2022-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/0001725160-22-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/zntl-20220525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-22-000114
- JSON: https://secwatch.observer/filing/0001725160-22-000114.json
- Plain text: https://secwatch.observer/filing/0001725160-22-000114.txt

## Key facts
- Executive change
  Cam S. Gallagher was appointed as President at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: President
  source text: On May 25, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the “Commencement Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/0001725160-22-000114-index.htm
- Executive change
  Kimberly Blackwell departed as President at Zentalis Pharmaceuticals, Inc..
  - Action: departed
  - Role: President
  source text: succeeding Kimberly Blackwell in such role
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000114/0001725160-22-000114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.